Abstract | OBJECTIVE: METHODS: Patients aged 12 years and older who completed phase II or III randomized, double-blind, placebo-controlled studies could enter an OLEx study, each comprising a blinded conversion period followed by an open-label maintenance period (32-424 weeks; maximum perampanel dose = 12 mg/d). Exposure, seizure outcomes, and treatment-emergent adverse events (TEAEs) were analyzed. RESULTS: Baseline characteristics were generally balanced between patients with FBTCS (n = 720) and GTCS (n = 138). Mean (standard deviation) cumulative duration of perampanel exposure was 102.3 (70.3) weeks (FBTCS) and 83.9 (38.4) weeks (GTCS). Retention rates were 50.0% for up to 4 years (FBTCS) and 49.2% for up to 2 years (GTCS). Across OLEx treatment durations, median reductions in seizure frequency per 28 days were 66.7% (FBTCS) and 80.6% (GTCS). Fifty percent and 75% responder and seizure-freedom rates were 59.5%, 45.3%, and 18.4%, respectively (FBTCS), and 72.5%, 51.5%, and 16.7%, respectively (GTCS). Efficacy was sustained for up to 4 years (FBTCS) and up to 3 years (GTCS), even when accounting for early dropouts. TEAE incidence was highest during Year 1 (FBTCS, 85.3%; GTCS, 86.2%); most common were dizziness and somnolence. During Year 1, serious TEAEs were reported in 81 (11.3%; FBTCS) and 10 (7.2%; GTCS) patients. TEAEs were consistent with the known safety profile of perampanel; no new safety signals were identified with long-term treatment. SIGNIFICANCE: This post hoc analysis suggests long-term (up to 4 years) adjunctive perampanel (up to 12 mg/d) is efficacious and well tolerated in patients (aged 12 years and older) with FBTCS or GTCS.
|
Authors | Ivan Rektor, Gregory L Krauss, Yushi Inoue, Sunao Kaneko, Betsy Williams, Anna Patten, Manoj Malhotra, Antonio Laurenza, Robert T Wechsler |
Journal | Epilepsia
(Epilepsia)
Vol. 61
Issue 7
Pg. 1491-1502
(07 2020)
ISSN: 1528-1167 [Electronic] United States |
PMID | 32645213
(Publication Type: Clinical Trial, Phase II, Clinical Trial, Phase III, Journal Article, Multicenter Study, Randomized Controlled Trial, Research Support, Non-U.S. Gov't)
|
Copyright | © 2020 The Authors. Epilepsia published by Wiley Periodicals LLC on behalf of International League Against Epilepsy. |
Chemical References |
- Anticonvulsants
- Nitriles
- Pyridones
- perampanel
|
Topics |
- Adolescent
- Adult
- Anticonvulsants
(administration & dosage, adverse effects)
- Dizziness
(chemically induced)
- Double-Blind Method
- Drug Therapy, Combination
- Female
- Follow-Up Studies
- Humans
- Male
- Middle Aged
- Nitriles
- Pyridones
(administration & dosage, adverse effects)
- Seizures
(diagnosis, drug therapy, epidemiology)
- Sleepiness
- Time Factors
- Treatment Outcome
- Young Adult
|